Lv11
30 积分 2025-06-23 加入
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
6小时前
已完结
Molecular Mechanisms Behind the Dose-Dependent Differential Activation of MAPK Pathways Induced by Transforming Growth Factor-β1 in Hematopoietic Cells
1个月前
已完结
Single-cell profiling reveals altered immune landscape and impaired NK cell function in gastric cancer liver metastasis
2个月前
已完结
Cellular and molecular mechanisms of gastrointestinal cancer liver metastases and drug resistance
2个月前
已完结
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
3个月前
已完结
First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer
3个月前
已关闭
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
3个月前
已完结
皖公网安备34019202002308
